RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
L. Conejero Hall (Madrid, Spain), L. Puente Maestu (Madrid, Spain), M. Calle Rubio (Madrid, Spain), W. Girón (Madrid, Spain), C. Alvarez Martínez (Madrid, Spain), M. Buendía García (Madrid, Spain), J. Serra Batllés (Barcelona, Spain), J. Rodríguez Hermosa (Madrid, Spain), S. Alonso Viteri (Madrid, Spain), J. García De Pedro (Madrid, Spain), P. Benedetti (Madrid, Spain), J. De Miguel Díez (Madrid, Spain), J. Alvarez-Sala Walther (Madrid, Spain), J. Hernández Vázquez (Madrid, Spain), F. García Río (Madrid, Spain), C. Rodríguez Sainz (Madrid, Spain), C. Fernández Pérez (La Coruña, Spain), A. Doyle (Madrid, Spain), R. Caballero (Madrid, Spain), J. Subiza (Madrid, Spain), M. Casanovas (Madrid, Spain), E. Fernández-Cruz (Madrid, Spain)
Source: Virtual Congress 2021 – ALERT: COPD
Session: ALERT: COPD
Session type: Clinical trials session
Number: 207
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Conejero Hall (Madrid, Spain), L. Puente Maestu (Madrid, Spain), M. Calle Rubio (Madrid, Spain), W. Girón (Madrid, Spain), C. Alvarez Martínez (Madrid, Spain), M. Buendía García (Madrid, Spain), J. Serra Batllés (Barcelona, Spain), J. Rodríguez Hermosa (Madrid, Spain), S. Alonso Viteri (Madrid, Spain), J. García De Pedro (Madrid, Spain), P. Benedetti (Madrid, Spain), J. De Miguel Díez (Madrid, Spain), J. Alvarez-Sala Walther (Madrid, Spain), J. Hernández Vázquez (Madrid, Spain), F. García Río (Madrid, Spain), C. Rodríguez Sainz (Madrid, Spain), C. Fernández Pérez (La Coruña, Spain), A. Doyle (Madrid, Spain), R. Caballero (Madrid, Spain), J. Subiza (Madrid, Spain), M. Casanovas (Madrid, Spain), E. Fernández-Cruz (Madrid, Spain). RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations. 207
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021
Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022
Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009
A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008
Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007
Preventive effect of carbocysteine on exacerbation of asthma, GAIA randomised, placebo-controlled multi-centre study Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care Year: 2017
Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial Source: International Congress 2019 – Airway infection in COPD Year: 2019
Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial Source: Eur Respir J 2002; 20: Suppl. 38, 146s Year: 2002
Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Recombinant human deoxyribonuclease (rhDNase) for the treatment of acute asthma in children: a multicentre randomised double-blind clinical trial Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007
Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial Source: International Congress 2016 – Asthma management Year: 2016
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006